What’s Next: Life Sciences at a Crossroads

Diving into the recent drug executive orders and the latest on BIOSECURE. We’ll review highlights from the Trump 47 Executive Orders on Lowering Drug Prices and Increasing Domestic Manufacturer and Regulatory Relief to Promote Domestic Production of Critical Medicines and Washington’s current view of the biotech industry’s relationship with China. We’ll cover topics including rare disease impact, most favored nation pricing, and government recommendations for the future of U.S. drug production.

• Elizabeth Mulkey, Partner, Goodwin
• Matt Wetzel, Partner, Goodwin

REGISTER

Exploring strategic collaborations and key considerations arising from down-round financings, bridge rounds, and other restructuring scenarios.

• William Collins, Partner, Goodwin
• Noelle Dubiansky, Partner, Goodwin

Covering product development and confidentiality, and their evolving impact on business strategy.

• Cathy McCarty, Partner, Goodwin
• Alan Crane, Entrepreneur Partner, Polaris Partners

Seeing how public biotechs manage a tough financing environment – including different approaches to financing on new data; trends in PIPEs, RDs, and CMPOs; strategic burn and development decisions; big pharma trends; changes in reverse mergers; royalty financing news; use of ATMs.

Speakers:

• Sam Zucker, Partner, Goodwin
• Michael Brinkman, Managing Director, Joint US Head of Biopharmaceuticals, Jefferies
• Nimish Shah, Partner, Venrock
• Sean McCarthy, CEO and Chairman, CytomX Therapeutics, Inc.

Covering royalty monetizations, PIPEs, debt capital markets, and other creative capital strategies to help carry you through a challenging and uncertain market.

Speakers:

• Felipe Heiderich, Partner, Goodwin
• Jacqueline Mercier, Partner, Goodwin
• Edwin O’Connor, Partner and Co-Chair, Capital Markets, Goodwin
• Kalli Dircks, Managing Director and Co-Head of Healthcare ECM, Morgan Stanley